One-pill combination for heart failure in India
Heart Failure Polypill in India: A Late-Stage Implementation Strategy
This project looks at whether giving adults in India a single pill that combines three guideline heart-failure medicines can lower deaths and hospital stays for people with reduced heart pumping function.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11243527 on NIH RePORTER |
What this research studies
From a patient's perspective, the team will first talk with doctors, patients, and local stakeholders to design a polypill approach that fits care in India. Then, adults with heart failure and reduced ejection fraction will be randomly assigned at multiple hospitals to either usual care or a care plan that uses the HFrEF polypill (a beta-blocker, an angiotensin receptor blocker, and a mineralocorticoid receptor antagonist combined). The trial will follow people for 12 months to track heart-related deaths and hospitalizations, while also collecting information on how the polypill is used in real-world clinics. The study aims to simplify treatment so more patients can get the full set of guideline medicines sooner.
Who could benefit from this research
Good fit: Adults in India with heart failure and reduced ejection fraction who are candidates for guideline-directed medical therapy would be the ideal participants.
Not a fit: People without reduced ejection fraction, those already on fully optimized individualized multi-drug regimens, or those with contraindications to the included drug classes are unlikely to benefit from this polypill approach.
Why it matters
Potential benefit: If successful, this could make it much easier for people with HFrEF to get the medicines that lower the risk of death and hospital stays.
How similar studies have performed: Combination 'polypill' approaches have shown promise in other cardiovascular prevention settings, but using a single pill specifically for HFrEF is relatively new and not yet widely tested.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Agarwal, Anubha — Washington University
- Study coordinator: Agarwal, Anubha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.